Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,976.00GBp
20 Apr 2018
Change (% chg)

20.50 (+0.41%)
Prev Close
4,955.50
Open
4,971.50
Day's High
4,986.50
Day's Low
4,960.00
Volume
1,448,352
Avg. Vol
2,105,655
52-wk High
5,585.07
52-wk Low
4,260.00

Latest Key Developments (Source: Significant Developments)

Ionis And AstraZeneca Advance New Drug For NASH
Monday, 9 Apr 2018 

April 9 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS AND ASTRAZENECA ADVANCE NEW DRUG FOR NASH.IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX.IONIS PHARMACEUTICALS INC - ASTRAZENECA WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT & COMMERCIALIZATION OF IONIS-AZ6-2.5-LRX.IONIS PHARMACEUTICALS INC - AS IONIS-AZ6-2.5-LRX ADVANCES, CO MAY RECEIVE UP TO $300 MLN IN ADDITIONAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS.  Full Article

Astrazeneca Announces Renewed U.S. Recommendation, Availability Of Flumist Quadrivalent Vaccine
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - AstraZeneca PLC ::ASTRAZENECA ANNOUNCES RENEWED RECOMMENDATION AND AVAILABILITY OF FLUMIST QUADRIVALENT VACCINE IN THE US.ASTRAZENECA - RESULTS DEMONSTRATED NEW 2017-2018 H1N1 LAIV POST-PANDEMIC STRAIN PERFORMED BETTER THAN 2015-2016 H1N1 LAIV POST-PANDEMIC STRAIN​.ASTRAZENECA - CDC'S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VOTED IN FAVOR OF RENEWED RECOMMENDATION FOR FLUMIST QUADRIVALENT USE IN U.S. 2018-2019 SEASON.  Full Article

Astrazeneca Says ‍Fasenra Receives EU Approval
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Astrazeneca Plc ::‍FASENRA RECEIVES EU APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA​.ASTRAZENECA - ‍FASENRA IS ALSO UNDER REGULATORY REVIEW IN JAPAN AND SEVERAL OTHER COUNTRIES, WITH EXPECTED REGULATORY DECISIONS IN H1 2018​.  Full Article

Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS ANNOUNCES EXPANDED RESEARCH COLLABORATION WITH ASTRAZENECA.MYRIAD GENETICS INC - FINANCIAL TERMS WERE NOT DISCLOSED..MYRIAD GENETICS INC - UNDER AGREEMENT, MYRIAD WILL USE ITS MYCHOICE HRD PLUS TEST TO EVALUATE PATIENTS ENROLLED IN AN ONGOING PHASE III TRIAL.  Full Article

Ani Pharmaceuticals Acquires Four NDAs From AstraZeneca For $46.5 Mln
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.  Full Article

Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain
Friday, 22 Dec 2017 

Dec 22 (Reuters) - ALMIRALL SA ::EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN).LICENSE AGREEMENT GRANTS ALMIRALL EXCLUSIVE RIGHTS TO COMMERCIALIZE CRESTOR AND PROVISACOR IN SPAIN.  Full Article

Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Astrazeneca Plc ::PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING.  Full Article

Chembio Diagnostics And Astrazeneca Collaborates To Develop Point-Of-Care Diagnostic Test
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Astrazeneca Plc ::CHEMBIO DIAGNOSTICS AND ASTRAZENECA ENTER A COLLABORATION TO DEVELOP POINT-OF-CARE DIAGNOSTIC TEST.CHEMBIO DIAGNOSTICS INC - UNDER TERMS OF 18-MONTH AGREEMENT, CO WILL RECEIVE UP TO $2.9 MILLION IN FUNDING FROM ASTRAZENECA.  Full Article

US FDA Accepts Regulatory Submission For Tagrisso (Osimertinib) In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Astrazeneca Plc ::US FDA ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO (OSIMERTINIB) IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER.  Full Article

US FDA Accepts Tagrisso Submission For 1St-Line Nsclc
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Astrazeneca Plc ::FDA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC.‍US FDA ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER​.  Full Article

UPDATE 1-UK Stocks-Factors to watch on April 19

April 19 Britain's FTSE 100 index is seen opening 6 points higher at 7,323 on Thursday, according to financial bookmakers, with futures up 0.12 pct ahead of the cash market open.